Message from the Chairman and CEO
Net sales and operating profit rose, owing to generally robust business performance in all geographic regions.
Profit attributable to owners of the parent was down, reflecting the impact of the revision of a tax treaty with Germany in the previous fiscal year.
During the first six months of the fiscal year ending March 31, 2018, net sales increased, due to generally firm business performance in all geographic regions. Operating profit also expanded, due in part to the effect of higher sales, but profit attributable to owners of the parent was down, reflecting the impact of the revision of a tax treaty with Germany in the previous fiscal year. Net sales rose 10.4% year on year, and operating profit increased 3.6%, while profit attributable to owners of the parent fell 18.3%. At the exchange rates prevailing one year earlier, net sales would have been up 6.1% and operating profit up 4.4%.
In Japan, sales edged up due to higher sales of reagents, mainly in the hemostasis and immunochemistry fields. Overseas, sales grew as the result of higher reagent sales in the hematology1 and hemostasis fields. As a result, the Group’s overseas sales ratio was 83.9%.
The yen has depreciated more than assumed in our initial forecasts of consolidated financial results for the fiscal year ending March 31, 2018. We have revised our assumed exchange rates accordingly, and we now expect year-on-year increases of 12.0% for net sales, 12.2% for operating profit and 2.1% for profit attributable to owners of the parent.
We forecast annual dividends of ¥60 per share (interim dividend of ¥30, year-end dividend of ¥30), in line with our initial forecasts.
1 Hematology field: The field of in vitro diagnostics that determines whether precise testing is necessary by analyzing the number, type and size of red, white and other blood cells.